Method for modulating glucagon-like peptide 1 (glp-1) agonist induced muscle loss
AssigneeCelularity Inc.
InventorsSharmila KOPPISETTI, Robert J. HARIRI, Joseph GLEASON, Rajarajeswari SIVALENKA, Lin KANG, Anna GOSIEWSKA
Life of this patent
Estimating the term…
Abstract
Provided herein is a method of ameliorating muscle loss in a subject induced from the treatment of the subject with a GLP-1 agonist with the administration to the subject of a therapeutically effective amount of a placenta derived biological material having a continuous lipid bilayer membrane
Claims18
A method for modulating Glucagon-Like Peptide 1 (GLP-1) agonist induced muscle loss in a subject being treated with a GLP-1 agonist, comprising administrating to the subject a therapeutically effective amount of a placenta derived biological material having a continuous lipid bilayer membrane, an umbilical cord derived biological material having a continuous lipid bilayer membrane, or a combination thereof.
A method for modulating GLP-1 agonist induced muscle loss in a subject being treated with a GLP-1 agonist, comprising the administration to the subject of a therapeutically effective amount of:
- (a) a population of placenta derived adherent cells;
- (b) exosomes secreted from placenta derived adherent cells;
- (c) secretomes isolated from placenta;
- or
- (d) any combination of (a)-(c).
Dependencies are inferred from the claim text.